Opportunity Information: Apply for RFA HL 19 020
The Molecular Atlas of Lung Development Program (LungMAP) Phase 2 Research Centers funding opportunity (RFA HL 19 020) is a National Heart, Lung, and Blood Institute (NHLBI) cooperative agreement (U01) designed to expand and deepen an open-access reference resource focused on human lung development. The central goal of LungMAP is to create a comprehensive, dynamic, three-dimensional molecular atlas of the developing lung, with integrated datasets and research reagents made broadly available to the scientific community. In Phase 2, NHLBI is specifically seeking Research Centers (RCs) that will generate high-resolution molecular profiling data and pair those data with spatial information so that investigators can map which molecules are present, where they are located in the tissue, and how they change across developmental stages and disease states. Clinical trials are not allowed under this announcement.
Phase 2 continues the programmatic emphasis on multiscale and high-resolution approaches, meaning the expectation is not simply to collect isolated datasets, but to produce molecular profiles that can be connected across different levels of biological organization (for example, tissue architecture, distinct anatomical regions, and individual cell types) and across time. A major scientific deliverable is molecular characterization of functionally and anatomically defined cell types in the developing human lung, supported by spatial context so that the resulting atlas is more than a list of genes or proteins and instead reflects the real organization of the lung as it forms and matures. The “dynamic” aspect of the atlas underscores that development is a process, and the resource is meant to capture transitions, maturation states, and evolving cellular composition rather than a single snapshot.
A key shift in Phase 2 is its exclusive focus on human lung, along with an expanded developmental window. Rather than concentrating only on late-stage development, Phase 2 extends coverage through normal lung development into early adulthood, defined here as up to 25 years of age. In addition, Phase 2 broadens the scope beyond normal development to include abnormal lung development in selected neonatal and pediatric rare lung diseases. This means the program is intended not only to define what typical human lung development looks like at molecular and spatial levels, but also to provide reference points for understanding how specific rare developmental disorders diverge from typical pathways, potentially clarifying disease mechanisms and highlighting cellular or molecular targets for future research.
The role of funded Research Centers under this opportunity is to serve as primary generators of molecular profiling data for the program. Because this is a cooperative agreement (U01), awardees should generally expect substantial scientific and programmatic involvement from the NIH compared with a standard research project grant, with coordination and alignment around shared goals, common standards, and resource-building priorities. The emphasis on an open-access reference resource also signals that data and reagents produced are expected to be shared with the broader community in a timely manner and in ways that support reuse, integration, and comparative analyses by outside investigators.
From an administrative and funding standpoint, the opportunity is offered by the Department of Health and Human Services through the National Institutes of Health (NIH), with the NHLBI as the sponsoring institute. The activity category is Health, and the CFDA number listed is 93.838. NHLBI anticipated making about four awards, with an award ceiling of $600,000. The original posting indicates a creation date of July 27, 2018 and an original closing date of October 31, 2018.
Eligibility is broad and includes many common organizational types that participate in NIH research, such as public and private institutions of higher education, nonprofit organizations (with or without 501(c)(3) status), for-profit organizations (other than small businesses), small businesses, and multiple levels of government entities (state, county, city or township, special districts), as well as Native American tribal governments and tribal organizations, and public housing authorities/Indian housing authorities. Importantly, applicants do not need to have been funded under LungMAP Phase 1 to apply for Phase 2, which opens the competition to new teams that can contribute the needed molecular and spatial profiling capabilities and can operate effectively in a coordinated, consortium-style environment.Apply for RFA HL 19 020
- The Department of Health and Human Services, National Institutes of Health in the health sector is offering a public funding opportunity titled "Molecular Atlas of Lung Development Program (LungMAP) Phase 2 Research Centers (U01- Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.838.
- This funding opportunity was created on Jul 27, 2018.
- Applicants must submit their applications by Oct 31, 2018. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $600,000.00 in funding.
- The number of recipients for this funding is limited to 4 candidate(s).
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the LungMAP Phase 2 Research Centers funding opportunity?
This opportunity is the Molecular Atlas of Lung Development Program (LungMAP) Phase 2 Research Centers funding announcement (RFA HL 19 020). It is an NHLBI cooperative agreement (U01) intended to expand and deepen an open-access reference resource focused on human lung development.
Which NIH institute is sponsoring this program?
The sponsoring institute is the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS).
What is the main goal of LungMAP Phase 2?
The central goal is to create a comprehensive, dynamic, three-dimensional molecular atlas of the developing human lung, with integrated datasets and research reagents made broadly available to the scientific community as an open-access resource.
What does “dynamic” mean in the context of this atlas?
“Dynamic” means the resource is intended to capture development as a process over time, including transitions, maturation states, and changing cellular composition, rather than representing a single static snapshot.
What kinds of data are Phase 2 Research Centers expected to generate?
Research Centers are expected to generate high-resolution molecular profiling data and pair those data with spatial information so investigators can determine which molecules are present, where they are located in the tissue, and how they change across developmental stages and disease states.
Why is spatial information emphasized?
Spatial information supports mapping molecular signals back to tissue organization, allowing the atlas to reflect the real architecture of the lung as it forms and matures rather than being only a list of genes or proteins.
What does “multiscale and high-resolution approaches” mean for expected deliverables?
The expectation is not just to produce isolated datasets. Instead, Phase 2 emphasizes molecular profiles that can be connected across different levels of biological organization (such as tissue architecture, anatomical regions, and individual cell types) and across time.
Is Phase 2 focused on human lung only, or does it include model organisms?
Phase 2 has an exclusive focus on human lung.
What age range does Phase 2 cover for normal lung development?
Phase 2 extends coverage through normal lung development into early adulthood, defined as up to 25 years of age.
Does the program include disease, or only normal development?
In addition to normal development, Phase 2 includes abnormal lung development in selected neonatal and pediatric rare lung diseases, providing reference points for how specific disorders diverge from typical developmental pathways.
What is a major scientific deliverable mentioned for Phase 2?
A major deliverable is molecular characterization of functionally and anatomically defined cell types in the developing human lung, supported by spatial context so the atlas reflects organized tissue structure and developmental change.
What role do funded Research Centers play in LungMAP Phase 2?
Funded Research Centers are described as primary generators of molecular profiling data for the program, contributing to shared resource-building goals.
What does it mean that this is a cooperative agreement (U01)?
As a cooperative agreement (U01), awardees should generally expect substantial scientific and programmatic involvement from NIH compared with a standard research project grant, including coordination and alignment around shared goals, common standards, and resource-building priorities.
Are awardees expected to share data and reagents?
Yes. Because LungMAP is framed as an open-access reference resource, data and reagents produced are expected to be shared broadly and in a timely manner to support reuse, integration, and comparative analyses by the wider scientific community.
Are clinical trials allowed under this funding opportunity?
No. Clinical trials are not allowed under this announcement.
What is the activity category for this opportunity?
The activity category listed is Health.
What is the CFDA number associated with this opportunity?
The CFDA number listed is 93.838.
How many awards did NHLBI anticipate making?
NHLBI anticipated making about four awards.
What is the award ceiling for this opportunity?
The award ceiling is listed as $600,000.
What are the key dates provided for the opportunity?
The original posting indicates a creation date of July 27, 2018 and an original closing date of October 31, 2018.
Who is eligible to apply?
Eligibility is broad and includes public and private institutions of higher education; nonprofit organizations (with or without 501(c)(3) status); for-profit organizations (other than small businesses); small businesses; and various government entities (state, county, city or township, special districts), as well as Native American tribal governments and tribal organizations, and public housing authorities/Indian housing authorities.
Do applicants need to have been funded under LungMAP Phase 1 to apply?
No. Applicants do not need to have been funded under LungMAP Phase 1 to apply for Phase 2.
What kind of teams is Phase 2 trying to attract?
Phase 2 is open to new teams that can contribute molecular and spatial profiling capabilities and can operate effectively in a coordinated, consortium-style environment aligned with shared standards and program goals.
What is the overall purpose of including rare neonatal and pediatric lung diseases?
Including selected rare diseases is intended to help clarify how abnormal developmental pathways diverge from typical development, potentially illuminating disease mechanisms and pointing to cellular or molecular targets for future research.
Browse more opportunities from the same category: Health
Next opportunity: Canoemobile: Engaging Youth on their Local Rivers
Previous opportunity: Yukon River Treaty Project Implementation
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HL 19 020
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HL 19 020) also looked into and applied for these:
| Funding Opportunity |
|---|
| Molecular Atlas of Lung Development Program (LungMAP) Phase 2 - Human Tissue Core (U01- Clinical Trial Not Allowed) Apply for RFA HL 19 021 Funding Number: RFA HL 19 021 Agency: Department of Health and Human Services, National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| Healthy Tomorrows Partnership for Children Program (HTPCP) Apply for HRSA 19 055 Funding Number: HRSA 19 055 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Enhancing Public Health Surveillance of Autism Spectrum Disorder through the Autism and Developmental Disabilities Monitoring (ADDM) Network Apply for CDC RFA DD19 1901 Funding Number: CDC RFA DD19 1901 Agency: Department of Health and Human Services, Centers for Disease Control - NCBDDD Category: Health Funding Amount: $775,000 |
| Enhance Population Access to Comprehensive HIV/AIDS Services in Order to Achieve HIV/AIDS Epidemic Control in the Democratic Republic of Congo (DRC), Specifically in Kinshasa under the President's Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH19 1934 Funding Number: CDC RFA GH19 1934 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: $3,000,000 |
| Initiative for TB/HIV Program Collaboration and Service Integration in the Central America Region under the President's Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH19 1947 Funding Number: CDC RFA GH19 1947 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: $1,500,000 |
| Develop, Implement, and Sustain High Quality Comprehensive HIV Cascade Activities for Children, Adolescents, and Adults in Facility and Community Based Settings in Cameroon under the President`s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH19 1916 Funding Number: CDC RFA GH19 1916 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: $34,000,000 |
| Innovating for HIV Impact: The South African HIV Innovations Accelerator Apply for SA HIV INNOVATIONS 2018 Funding Number: SA HIV INNOVATIONS 2018 Agency: Agency for International Development Category: Health Funding Amount: $1,500,000 |
| State Primary Care Offices Apply for HRSA 19 005 Funding Number: HRSA 19 005 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Service Area Competition Apply for HRSA 19 015 Funding Number: HRSA 19 015 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Implementing Evidence-Based Prevention Interventions for Key and Priority Populations in the Republic of Rwanda under the President's Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH19 1940 Funding Number: CDC RFA GH19 1940 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: $2,514,175 |
| Strengthening the Ministry of Health's Capacity to Sustain and Expand Quality HIV Prevention, Care and Treatment Services for People Living with HIV in Vietnam through Focused Direct Service Support, Technical Assistance, and Innovations under P Apply for CDC RFA GH19 1904 Funding Number: CDC RFA GH19 1904 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: $6,000,000 |
| Strengthening the Health System Capacity to Implement HIV Prevention, Care, and Treatment Services in the Republic of South Africa under the President's Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH19 1920 Funding Number: CDC RFA GH19 1920 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: $30,000,000 |
| Strengthening Vietnam's Indigenous Technical Assistance Capacity and Systems through Support for HIV/AIDS Clinical Mentorship and Health System Strengthening under the President's Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH19 1930 Funding Number: CDC RFA GH19 1930 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: $1,500,000 |
| Accelerating the Coordination of Health Policy and Strategies for HIV/AIDS Treatment Services through the Tanzania Commission for AIDS (TACAIDS) in the United Republic of Tanzania under the President's Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH19 1918 Funding Number: CDC RFA GH19 1918 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: $500,000 |
| Novel and Innovative Tools to Facilitate Identification, Tracking, Manipulation, and Analysis of Glycans and their Functions (U01 Clinical Trial Not Allowed) Apply for RFA RM 18 036 Funding Number: RFA RM 18 036 Agency: Department of Health and Human Services, National Institutes of Health Category: Health Funding Amount: $320,000 |
| Accelerating the Implementation of Health Policy and Strategies for HIV/AIDS Treatment Services through the President's Office - Regional Administration and Local Government (PO-RALG) in the United Republic of Tanzania under PEPFAR Apply for CDC RFA GH19 1956 Funding Number: CDC RFA GH19 1956 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: $500,000 |
| Ensuring High Quality in Mentor Mother Strategy Implementation: Helping Mothers Eliminate Pediatric HIV in Mozambique under the President's Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH19 1903 Funding Number: CDC RFA GH19 1903 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: $5,000,000 |
| Pediatric Immunotherapy Discovery and Development Network (PI-DDN)(U54 - Clinical Trial Not Allowed) Apply for RFA CA 19 003 Funding Number: RFA CA 19 003 Agency: Department of Health and Human Services, National Institutes of Health Category: Health Funding Amount: $1,600,000 |
| Strengthening the Public Health System in the U.S.-Affiliated Pacific Islands Apply for CDC RFA OT16 16010301SUPP18 Funding Number: CDC RFA OT16 16010301SUPP18 Agency: Department of Health and Human Services, Centers for Disease Control - OSTLTS Category: Health Funding Amount: $1,000,000 |
| Strategic Information Support Across Countries under the Global Fund to Fight HIV/AIDS, Tuberculosis and Malaria and under the President's Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH19 1951 Funding Number: CDC RFA GH19 1951 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: $10,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HL 19 020", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.